Circulating Osteopontin Predicts Clinical and Radiological Response in First-Line Treatment of Advanced Non-Small...

Area of Science:

• Oncology
• Immunotherapy
• Biomarker Discovery

Background:

• Pembrolizumab efficacy in non-small cell lung cancer (NSCLC) is limited by resistance mechanisms.
• Osteopontin (OPN) is an emerging biomarker associated with senescence and NSCLC progression.

Purpose of the Study:

• To investigate the predictive value of serum osteopontin (OPN) in patients with advanced NSCLC receiving first-line pembrolizumab-based regimens.
• To assess the association of OPN with treatment response and survival outcomes.

Main Methods:

• Seventy-nine patients with advanced NSCLC receiving first-line pembrolizumab were enrolled.
• Serum OPN levels were analyzed for their predictive value regarding progression disease (PD) and overall survival (OS).
• Performance status (ECOG) and early response were also evaluated.

Main Results:

• High serum OPN levels were associated with worse baseline ECOG performance status (p=0.015).
• Elevated OPN predicted progression disease (PD) and death at first (OR 1.17) and best response assessments (OR 0.04).
• OPN demonstrated predictive value for iRECIST-PD (HR 1.01), RECIST-PD (HR 1.01), and OS (HR 1.02).

Conclusions:

• Baseline serum osteopontin (OPN) is a significant predictor of outcomes in advanced NSCLC patients undergoing pembrolizumab therapy.
• OPN may serve as an upfront biomarker for senescence, guiding future research in NSCLC treatment strategies.